IPO in Chinese Mainland Stock Markets

• Innovita Biological Technology Co., Ltd. (688253.SH) IPO on SSE STAR Market (2022)

• Dizal Pharmaceutical Co., Ltd. (688192.SH) IPO on SSE STAR Market (2021)

• GalaxyCore, Inc. (688728.SH) IPO on SSE STAR Market (2021)

• Beijing Novogene Co., Ltd. (688315.SH) IPO on SSE STAR Market (2021)

• Ninebot Limited (689009.SH) IPO on SSE STAR Market (2020) (the first case that a red-chip company offers CDR to be listed on Chinese stock markets)

• Taiho Photoelectricity Co. Ltd. (603656.SH) IPO on SSE Main Board (2017)

• Jiangsu Riying Electronics Co., Ltd. (603286.SH) IPO on SSE Main Board (2017)

IPO in Hong Kong & Overseas Stock Markets

• Biocytogen Pharmaceuticals (Beijing) Co., Ltd. IPO on the Main Board of HKEX (2022) 

• Jiangsu Recbio Technology Co., Ltd. (02179.HK) IPO on the Main Board of HKEX (2022)

• Nano Labs Limited (NA) IPO on Nasdaq (2022)

• SenseTime Group Inc. (0020.HK) IPO on the Main Board of HKEX (2021)

• Antengene Corporation Limited (06996.HK) IPO on the Main Board of HKEX (2020)

• Canaan Inc. (CAN) IPO on Nasdaq (2019)

• Ascentage Pharma (6855.HK) IPO on the Main Board of HKEX (2019)

M&A and Major Assets Reorganization

• Acquisition of Le Belier (EUR 251 million) by Guangdong Wencan (603348.SH) (2020)

• Acquisition of Cloos Group by Nanjing Estun (002747.SZ) (2020)

• Acquisition of Krauss Maffei Group by Qingdao Tianhua Institute (600579.SH) (a subsidiary of ChemChina) (2019)

• Strategic Cooperation between Barrick Gold and Shandong Gold Mining (600574.SH) via Shandong Gold Mining's acquisition of 50% of Valadero Gold for USD 960 million (2018)

• China Cinda Asset Management Co. and Hainan Airlines to form acquisition fund (CNY 10 billion) to acquire Gategroup (2017)

• Acquisition of Super Sports Media by China Cinda Asset Management Co. and DDMC Group (600547.SH) (2017)

• Acquisition of Biejing Liujie by Jiaxun (300213.SZ) (2017)

Equity Investment and Financing

• Represented The Carlyle Group in its Series D investment into Abbisko Therapeutics Co., Ltd.

• Represented The Greater Bay Area Homeland Investment Fund in its Series C investment into Elpiscience Biopharma, Ltd.

• Represented PICC Equity Investment Fund in its Series B investment into Abogen Bio

• Represented Beijing Menlo Biotech Company in its VIE set-up and restructuring

• Represented Haitong Capital, Efung Capital and Huarong Rongde in their Series B investment into Jiangsu Gensciences 

• Represented BioTrack Capital in its Series A+ investment into Guangzhou Reforgene Medicine

• Represented BioTrack Capital in its Series B+ investment into Beijing EdiGene Biotech Company

• Represented Beijing Changmugu Medical Technology Co., Ltd. in its Series B and B+ financing

• Represented Forecyte Bio in its Series A financing

• Represented APRINOIA Therapeutics in its ESOP

• Represented Rinua Gene in its establishment and Series Seed financing

• Represented Rinua Gene in its VIE set-up and restructuring

• Represented CMG-SDIC Capital for its Series B investment into Inceptio Technology Company

• Represented Sequoia for its Series A+ investment into Orka Inc.

• Represented CMG-SDIC Capital for its Series A investment into Suzhou Porton Advanced Solutions

• Represented Asymchem Biotech Investment Fund, Suzhou Ribo Life Science Co., Ltd., and Asymchem in founding an API CMO joint venture

• Represented Gyee Capital in its Series D investment into SceneRay Medical Device Company

• Represented Lapam Capital in its Series A+ investment into Shanton Pharma Holdings Limited

• Represented Hongtai Aplus in its Series B investment into CGeneTech (Suzhou) Co., Ltd.

• Represented Huagai Capital in its Series B investment into Immvira Bioscience Inc.

• Represented Starquest Capital in its Series C and D investment into Miaoshou.net

• Represented SDIC Fund, Chinalifepe, Ping'an, and Taikang in their USD 260 million Series D investment in Innovent (red-chip structure)

• Represented CIIFUND in its investment in Kuaishou Technology (red-chip structure)

• Represented SDIC Fund in its Series B Investment in Ascentage Pharma

• Represented Huagai Capital in its investment in Shanghai Haihe Parma (red-chip structure)

• Represented Antengene Corporation in its red-chip restructure and Series B financing (red-chip structure)  

• Represented Antengene Corporation in its Series C financing (red-chip structure)

• Represented Huagai Capital in its Series B investment in Immvira 

• Represented Exegenesis in its Series B and B+ financing (red-chip structure)

• Represented Antengene Corporation in its ESOP project

• Represented New Horizon Fund in its investment in Connect Biopharma (red-chip structure)

• Represented New Alliance Capital in its investment in CF Pharmtech

• Represented Taikang Insurance in its investment in Viva Biotech

• Represented SDIC Fund and AstraZeneca in setting up a joint venture Dizal Jiangsu

• Represented Dizal Jiangsu in its Series A financing

• Represented SDIC Fund in its investment in Bright-Gene

• Represented CMG-SDIC Capital in its investment in Omni Pharma (red-chip structure)

• Represented Lapam Capital in its investment in Surefire Medical, Inc.

• Represented SDIC Fund in its investment in Novogene

• Represented China Life PE in its investment in Soyoung (online commerce of aesthetic medicine)

• Represented Starquest Capital in its Series C and D investment in Miaoshou.com (online OTC and internet hospital)

• Represented Lapam Capital in its investment in Asieris Pharmaceuticals

• Represented CMS China in its investment in Kingsoft Cloud (red-chip structure)

• Represented CMS China in its investment in To8To.com (red-chip structure)

• Represented CMS China in its investment in Qing Cloud (red-chip structure)

• Represented China Merchants Jintai Capital in its investment in Mobike (red-chip structure)

• Represented China Merchants Jintai Capital in its investment in Meituan.com (red-chip structure)

• Represented China MobileFund Management in its investment in Liepin.com (red-chip structure)